• Caribou Biosciences posted a GAAP net loss of USD 24.3 million, or USD 0.24 per share, in Q2 2026.
• Loss narrowed from USD 54.1 million, or USD 0.58 per share, a year earlier, which included USD 21.3 million in non-cash impairment.
• Revenue fell 43.8% to USD 1.5 million versus Q2 2025.
• R&D expenses dropped 31.6% to USD 18.9 million, due to lower external CMO/CRO activity and prior workforce reduction.
• Cash, cash equivalents and marketable securities totaled USD 113.8 million; runway expected to extend to end-2027, with funding options explored for ANTLER-3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.